AstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to treat adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the lawsuit filed by AstraZeneca (AZN) joining Johnson & Johnson (JNJ), Merck (MRK), and Bristol-Myers (BMY) in a lawsuit against the...

The UK Dividend Stocks Portfolio invests exclusively in dividend-paying FTSE All-Share stocks. Short-term returns can be extremely misleading because they are driven by the emotional ups and downs ...

AstraZeneca is facing two London lawsuits, including one from the husband of a woman who died after receiving the Anglo-Swedish drugmaker's COVID-19 vaccine, in the first of potentially dozens of c...

Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are...

There are sectors in the economy that go through an extended period of trending sideways to lower. A good example is the pharmaceutical sector.

CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chine...

AstraZeneca's phenomenal medicine portfolio pushed up revenue and profits in the second quarter. The company is committed to innovation.